IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call ...

IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ Chief Medical Advisor ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the financial performance of Tarsus’ only marketed product in the United States, Xdemvy, approved for demodex blepharitis. The company i ...

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids Demodex blepharitis is a significant eyelid disease that impacts approximately 25 million people in the U.S. – or 1 out of every 12 adults Media accompanying this announcement is available by clicking on this link IRVINE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and n ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell, thus laying a solid foundation for my current expertise. . As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vasuda Healthcare Ana ...

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Tarsus Pharma (NASDAQ:TARS) has an approved drug for a mite infestation eye disease called Demodex blepharitis and multiple late-stage assets in its pipeline. Its key molecule is called lotilaner, an antiparasitic widely used in veterinary medicine for the treatment of ticks, mites and other infestations. It's available in oral tablet forms and is known to be effective in animals. Tarsus has 3 product candidates, all of which are various formulat ...

Tarsus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call August 8, 2024 Today's Speakers Bobak Azamian, M.D., Ph.D. Chief Executive Officer and Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial Officer and Chief Strategy Officer 2 2 © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.20%. A quarter ago, it was expected that this company would post a loss of $1.15 per share when it actually produced a loss of $1.01, delivering a surprise of 12.17%. Over the last four quarters, the compa ...